Check for updates

OPEN ACCESS

EDITED BY Fausto Cremonesi, University of Milan, Italy

REVIEWED BY Katia Cappelli, University of Perugia, Italy Claudio Henriquez, Austral University of Chile, Chile

*CORRESPONDENCE Ju-Hyun An ⊠ anjuhyun@kangwon.ac.kr

RECEIVED 03 April 2024 ACCEPTED 21 June 2024 PUBLISHED 01 July 2024

CITATION

Lee J-S, Jeong Y-H, Kim Y-H, Yun J-H, Ahn J-O, Chung J-Y and An J-H (2024) Analyzing small RNA sequences from canine stem cell-derived extracellular vesicles primed with TNF- α and IFN- γ and exploring their potential in lung repair. *Front. Vet. Sci.* 11:1411886. doi: 10.3389/fvets.2024.1411886

COPYRIGHT

© 2024 Lee, Jeong, Kim, Yun, Ahn, Chung and An. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Analyzing small RNA sequences from canine stem cell-derived extracellular vesicles primed with TNF- α and IFN- γ and exploring their potential in lung repair

Ji-Sun Lee¹, Yun-Ho Jeong², Yo-Han Kim³, Jang-Hyuk Yun⁴, Jin-Ok Ahn², Jin-Young Chung² and Ju-Hyun An^{1*}

¹Department of Veterinary Emergency and Critical Care Medicine, College of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of Korea, ²Department of Veterinary Internal Medicine, College of Veterinary Medicine, Institute of Veterinary Science, Kangwon National University, Chuncheon, Republic of Korea, ³Department of Large Animal Internal Medicine, College of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of Korea, ⁴Department of Veterinary Pharmacology, College of Veterinary Medicine, Institute of Veterinary Science, Kangwon National University, Chuncheon, Republic of Korea

Acute lung injury is an acute inflammation disorder that disrupts the lung endothelial and epithelial barriers. In this study, we investigated the extracellular vesicles (EVs) obtained via priming inflammatory cytokines such as tumor necrosis factor (TNF)- α and interferon (IFN)- γ on canine adipose mesenchymal stem cells in improving their anti-inflammatory and/or immunosuppressive potential, and/or their ability to alleviate lipopolysaccharide-induced lung injury in vitro. We also explored the correlation between epithelial-to-mesenchymal transition and the inflammatory repressive effect of primed EVs. Using small RNA-Seq, we confirmed that miR-16 and miR-502 significantly increased in EVs from TNF- α and IFN- γ -primed canine adipose mesenchymal stem cells. The pro and anti-inflammatory cytokines were analyzed in a lipopolysaccharideinduced lung injury model and we found that the EV anti-inflammatory effect improved on priming with inflammatory cytokines. EVs obtained from primed stem cells effectively suppress endothelial-to-mesenchymal transition in a lung injury model. Our results suggest a potential therapeutic approach utilizing EVs obtained from adipose mesenchymal stem cells primed with TNF- α and IFN- γ against lung inflammation and endothelial to mesenchymal transition.

KEYWORDS

acute lung injury, canine, endothelial to mesenchymal transition, extracellular vesicle, stem cell

1 Introduction

Acute lung injury (ALI) is defined by hypoxemic respiratory insufficiency due to non-cardiogenic pulmonary edema resulting from increased pulmonary vascular permeability (1). Despite the reported mortality rate of over 90% in veterinary medicine, there is still a lack of specific and effective treatment methods for ALI (2).

Lung endothelial cells form the pulmonary vascular bed and constitute the majority of cells in the lungs. During ALI, systemic inflammation affects the pulmonary endothelium,

compromising the integrity of the alveolar capillary membrane and leading to the accumulation of edematous fluid in the lung parenchyma. Consequently, this cascade results in ventilation failure (3, 4). In addition to their role in gas exchange, lung endothelial cells create a specialized microenvironment, or niche, with significant implications for both health and disease. Therefore, the notion that the restoration of lung endothelial cells (ECs) is crucial for ALI treatment has garnered considerable attention.

Recent studies have highlighted a critical therapeutic role for extracellular vesicles (EV) secreted by mesenchymal stem cells (MSCs) in ALI (5, 6). EVs are nano-sized membrane-bound vesicles that transport essential biomolecules between cells to maintain physiological homeostasis. Research indicates that EVs derived from MSCs (MSC-EV) possess regenerative and anti-inflammatory properties (7, 8). Utilizing MSC-EVs as an alternative to MSCs offers several advantages, including a higher safety profile, lower immunogenicity, and the ability to traverse biological barriers. Moreover, ongoing studies aim to enhance the efficacy of stem cellderived extracellular vesicles. Among these efforts, the antiinflammatory efficacy of MSC-EVs has been augmented by priming stem cells with interferon (IFN)- γ and tumor necrosis factor (TNF)- α (9, 10). However, further research is necessary to ascertain the impact of applying MSC-EVs with enhanced therapeutic properties to lung diseases.

We hypothesized that primed EVs may enhance therapeutic effectiveness in repairing lung endothelial cells. To investigate this, we first investigated factors associated with tissue recovery by profiling miRNAs in canine MSC-EVs obtained after priming TNF- α and IFN- γ . We also used *in vitro* lung injury model, a lipopolysaccharide (LPS)-induced lung endothelial cell, to compare and analyze the degree of inflammation alleviation provided by primed and naive canine MSC-EVs.

2 Materials and methods

2.1 The Institutional Animal Care and Use Committee

This study was conducted following the protocols approved by the Institutional Animal Care and Use Committee of Kangwon National University (KNU), Republic of Korea, and in compliance with the authorized guidelines (KNU, Protocol No. KW-230912-3).

2.2 Isolating TNF- α and IFN- γ -primed canine adipose mesenchymal stem cell EVs

Stem cells were isolated from canine adipose tissue from 3 dogs and primed with inflammatory cytokines (TNF- α and IFN- γ) as previously described (9, 11). To summarize briefly, the canine adiposederived mesenchymal stem cells (cASCs) were seeded in 6-well plates at a density of 5×10^5 cells per well and cultured in Dulbecco's modified Eagle's medium with 4.5 g/L glucose (DMEM; PAN-Biotech, Aidenbach, Germany) supplemented with 10% Exo-free fetal bovine serum (FBS; PAN-Biotech) and 1% penicillin-streptomycin (PS; PAN-Biotech). After 6 h, the cells were stimulated for 24 h with TNF- α (20 ng/mL, PROSPEC, Ness Ziona, Israel) and IFN- γ (20 ng/mL, Kingfisher Biotech, Saint Paul, MN). Then, the conditioned media in the 6-well plate was discarded and washed three times with DPBS (PAN-Biotech). To isolate EVs, cASCs were cultured for 48h in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% exosome-depleted fetal bovine serum (FBS; Thermo Fisher Scientific, MA, United States). Following incubation, the medium from each cultured cASC sample was harvested and centrifuged at 100×g for 5 min. Then, to exclude cells and cellular debris, each supernatant was transferred to a fresh tube and ExoQuick-CG Exosome Precipitation Solution (System Biosciences, CA, United States) was added at a 3:1 ratio of supernatant to ExoQuick-CG Exosome Precipitation Solution. After incubation in the refrigerator for 12h, the ExoQuick-CG/ supernatant mixture was centrifuged at 1,500×g for 30 min. After centrifugation, exosomes were identified as white pellets, and these exosomes were used in experiments. Exosome characterization was conducted in a previous study (10). Briefly, protein markers of isolated EVs were detected using western blotting with antibodies targeting CD81 (Aviva system biology, CA, United States) and CD9 (GeneTex, Irvine, CA, United States). The morphology of the EVs was assessed using transmission electron microscopy. Briefly, 10 µL of EV suspension was applied onto a 300-mesh formvar/carbon-coated electron microscopy grid with the coated side facing the suspension. The grid was washed with distilled water and then negatively stained with a 10 µL drop of uranyl acetate for 1 min. The EVs were observed under a transmission electron microscope (TEM; LIBRA 120, Carl Zeiss, Germany) operating at 120 kV. The size distribution of the particles was determined using a zeta-potential and particle size analyzer (ELSZ-1000ZS, Otsuka Electronics, Osaka, Japan). Total protein concentration of EVs was determined using bicinchoninic acid (BCA) assays (Bio-Rad lab, CA, United States).

2.3 Identifying miRNAs via small-RNA sequencing analysis

Small RNA sequencing assay was conducted by E-Biogen, Inc. (Seoul, Republic of Korea). Libraries for both Naive and primed EV RNAs were prepared using the NEBNext Multiplex Small RNA Library Prep kit (New England BioLabs, Inc., MA, United States) as per manufacturer's instructions. Initially, the total RNA from each sample was used for adaptor ligation, followed by complementary DNA (cDNA) synthesis using reverse transcriptase with adaptorspecific primers. Subsequently, polymerase chain reaction (PCR) amplification was performed to generate libraries, which were purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and subjected to polyacrylamide gel electrophoresis. The yield and size distribution of the small RNA libraries were assessed using an Agilent 2100 Bioanalyzer instrument with a High-sensitivity DNA Assay (Agilent Technologies, Inc., CA, United States). High-throughput sequencing was performed on a NextSeq550 system, employing single-end 75 sequencing (Illumina Inc., CA, United States). Sequence reads were aligned using the bowtie2 software tool to generate a BAM file with mature miRNA sequences serving as references for mapping. For determination of RNAseq, the software programs bedtools v2.25.0 (Quinlan and BEDTools), mirbase.db v1.2.0 and microRNA v1.58.0 in Bioconductor (12) were employed in conjunction with R statistical programming language (13) to map read counts onto mature miRNA sequences and extract them from the alignment file.

2.4 Canine lung-derived endothelial cell isolation

Stromal cells were isolated from the lung tissues obtained from three dogs. Tissue samples were obtained from one biopsy per dog and washed twice with Dulbecco's phosphate-buffered saline (DPBS; PAN-Biotech GmbH, Aidenbach, Germany) containing 1% penicillinstreptomycin (PS; PAN-Biotech). The washed tissues were plated on a Petri dish, digested with 10 mL of 0.1% Collagenase type 1A solution (Gibco/Life Technologies, MA, United States), and incubated for 50 min at 37°C in a humidified atmosphere with 5% carbon dioxide. Following digestion, DMEM (PAN-Biotech) supplemented with 10% FBS; (Sigma-Aldrich, MO, United States) and 1% PS was added to neutralize the collagenase. The suspension was centrifuged at $1,200 \times g$ for 5 min, the supernatant was discarded, and the cell pellet was resuspended in DMEM. The suspension was then passed through a 70 µm Falcon cell strainer (Thermo Fisher Scientific) to remove debris, followed by centrifugation at 1,200×g for 5 min. To remove erythrocytes, red blood cell lysis buffer (Sigma-Aldrich) was added and the cell suspension was incubated for 10 min at 25°C. The cells were washed with DPBS and the supernatant was discarded. The cells were then resuspended in DMEM.

Then, the cells were incubated with a canine CD31 antibody (dilution, 1:200; Invitrogen, CA, United States) for 1 h at 25°C, followed by centrifugation at $1,200 \times g$ for 5 min. Subsequently, the cells were incubated with anti-mouse immunoglobulin (Ig)-G microbeads (Miltenyi Biotec, CA, United States) for 1h at 25°C, followed by magnetic-activated cell sorting (MACS; Miltenyi Biotec) to isolate CD31⁺ cells according to the manufacturer's instructions. PBS with 10% FBS (PAN-Biotech) was used as the MACS separation buffer. The lung stromal cells were incubated with the CD31 antibody for 2h at 37°C in a humidified atmosphere with 5% carbon dioxide. CD31+ endothelial cells were collected after centrifugation at 780×g for 10 min. Magnetic labeling was performed via adding 10 µL of anti-mouse IgG microbeads and 40μ L MACS separation buffer to the CD31⁺ cells, followed incubation for 2h. The CD31⁺ cells were collected after centrifugation at 780×g for 10 min. After washing the MACS LS column with 3 mL MACS separation buffer, the CD31⁺ endothelial cells were added to it for isolation. After another wash with 3 mL MACS separation buffer, the cells were collected in 5 mL MACS separation buffer.

2.5 LPS-induced lung inflammation in vitro

To stimulate endothelial cells with LPS (Sigma-Aldrich), the cells were seeded at a density of 1×10^5 cells/mL in six-well plates. A control medium, devoid of LPS, was used alongside the experimental groups to which 200 ng/mL LPS was added. Following 24 h of incubation for stimulation, the medium was replaced with media containing EVs derived from naive (unstimulated) or primed (stimulated) cASCs at a concentration of 50 µg/mL (11). Subsequently, the cells were further incubated for 48 h before harvesting for RNA extraction and enzyme-linked immunosorbent assay (ELISA) analysis.

2.6 Cell proliferation assay

To examine the potential impact of LPS and EVs on canine lung endothelial cell proliferation, it was evaluated using a Cell Counting Kit-8 (CCK-8) assay (D-PlusTM CCK Cell Viability Assay Kit; Dong-In Biotech, Seoul, Republic of Korea). Endothelial cells were seeded at a density of 3.3×10^4 cells/well in 96-well plates. Following co-culture with LPS (200 ng/mL) and EVs (50 µg/mL), a CCK-8 assay was performed at either 24 or 48 h.

2.7 Evaluation of gene expression

RNA was extracted from lung endothelial cells at a density of 2.5×10^5 cells per well using the Easy-Blue Total RNA Extraction Kit (Intron Biotechnology, Sungnam, Republic of Korea) following the manufacturer's instructions. Subsequently, cDNA was synthesized using the Cell Script All-in-One 5x 1st cDNA Strand Synthesis Master Mix (Cell Safe, Seoul, Korea) containing M-MLV (Moloney Murine Leukemia Virus) reverse transcriptase (RTase), ribonuclease inhibitor, dNTPs and an optimized ratio of Oligo (dT)s and random primers. The synthesized cDNA samples were analyzed using the AMPIGENE qPCR Green Mix Hi-ROX with SYBR Green dye (Enzo Life Sciences, NY, United States) and forward and reverse primers (Bionics, Seoul, Republic of Korea). For relative quantification we used the $2^{-\Delta\Delta CT}$ method (14). The target gene expression levels were normalized to those of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primers utilized in this study targeted GAPDH, interleukin (IL)-1 β , TNF- α , IL-10, N-cadherin, Vimentin, and E-cadherin present in dogs, with sequences detailed in Table 1.

2.8 ELISA

To investigate the secretion of TGF- β 1 by lung endothelial cells in lung inflammation alongside canine stem cell EVs, the canine TGF- β 1 concentration in the endothelial cell culture supernatant was measured using a TGF- β 1 ELISA Kit (Novus Biologicals LLC, CO, United States), as per manufacturer's instructions.

TABLE 1 Sequences of PCR primers used in this study.

Gene	Forward (5'-3')	Reverse (5'-3')
Canine GAPDH	CCA TCT TCC AGG	TTC TCC ATG GTG
	AGC GAG AT	GTG AAG AC
Canine IL10	CGA CCC AGA CAT	CAC AGG GAA GAA
	CAA GAA CC	ATC GGT GA
Canine TNFA	CGT CCA TTC TTG	AGC CCT GAG CCC
	CCC AAA C	TTA ATT C
Canine IL1B	CCC TGG AAA TGT	CTG ACA CGA AAT
	GAA GTG CT	GCC TCA GA
Canine ECAD	AAA ACC CAC AGC	CAC CTG GTC CTT
	CTC ATG TC	GTT CTG GT
Canine NCAD	CCC AAG ACA AGC	TGA CAG CTG ACC
	GAC TAA GC	TGA GAT GG
Canine VIMENTIN	CCG ACA GGA TGT	TCA GAG AGG TCG
	TGA CAA TG	GCA AAC TT

2.9 Statistical analysis

Statistical analyses were conducted using GraphPad Prism version 6.01 software (GraphPad Software, CA, United States). Student's *t*-test and one-way analysis of variance (ANOVA) were used to analyze the data, followed by the Bonferroni multiple comparison test for post-hoc analysis. Results are expressed as mean ± standard deviation. Statistical significance was defined as p < 0.05. For RNAseq, the software programs bedtools v2.25.0 (Quinlan and BEDTools) and Bioconductor (12) were employed in conjunction with R statistical programming language (13) to map read counts onto mature miRNA sequences and extract them from the alignment file. These read counts were then used to assess miRNA expression levels using the CPM+TMM normalization method for inter-sample comparison.

3 Results

3.1 Comparing miRNA profiling between naive and primed cASC-derived EVs

Differential miRNA expression patterns were observed in EV samples derived from both naive and primed cASCs. The expression level of each gene is reported as the read count normalized to the \log_2 value. Out of 455 total dog miRNAs in miRbase¹ at the time of the analysis, 202 were dysregulated. Specifically, 95 miRNAs were upregulated, whereas 107 miRNAs were downregulated in primed cASC-derived EVs compared to their naive counterparts. A total of 11 miRNAs exhibited significant differences (p < 0.05) between naive and primed cASC-derived EVs (Figure 1).

3.2 Elevated miR-16 and miR-502 in primed cASC-derived EVs

In primed cASC-derived EVs, 11 miRNAs were significantly differentially expressed (p < 0.05, fold change >2.0). Among these, two miRNAs, miR-16 and miR-502, were upregulated, whereas the remaining nine miRNAs, miR-184, miR-132, miR-103, miR-107, miR-1, let-7f, let-7g, let-7c, and miR-143, were downregulated (Figure 2).

3.3 Proliferation of lung endothelial cells under naive and primed cASC-derived EVs

The potential impact of LPS and EVs on canine lung endothelial cell proliferation were investigated using the CCK-8 assay, and significant cell proliferation was confirmed in endothelial cells treated with naïve and primed EV after 48 h (p < 0.01). However, no significant differences were observed between the two groups (Figure 3).

3.4 TNF- α and IFN- γ -primed EVs derived from cASCs for mitigating lung inflammation

To evaluate the immunomodulatory potential of primed cASCderived EVs in lung inflammation, we analyzed the mRNA expression of anti- and proinflammatory cytokines in lung endothelial cells. Following LPS stimulation, TNF- α and IL-1 β showed elevated expression levels compared to unstimulated lung endothelial cells (p < 0.001). However, when LPS-stimulated lung endothelial cells were cultured with naive and primed cASC-derived EVs, the TNF- α and IL-1 β expression levels reduced (p < 0.01). We also assessed the mRNA expression of IL-10 and they were significantly elevated in LPS-stimulated lung endothelial cells cultured with primed cASCderived EVs compared to those cultured with naive cASC-derived EVs (p < 0.001). This suggests that primed cASC-derived EVs may possess enhanced immunomodulatory properties, as evidenced by the upregulation of IL-10 expression (Figure 4).

3.5 TGF- β 1 levels in lung endothelial cell-cultured media

The TGF- β 1 ELISA Kit was utilized to quantify TGF- β 1 levels in endothelial cell culture supernatant, either treated or not treated with naive and primed cASC-derived EVs. Among LPS treated groups, reduced TGF- β 1 levels were observed in the conditioned media treated with both naive and primed cASC-derived EVs compared to the untreated cASC conditioned media. Furthermore, in the group treated with primed cASC-derived EVs, a significant decrease was observed compared to that in the group treated with naive cASCderived EVs (p < 0.05) (Figure 5).

3.6 Inhibiting endothelial to mesenchymal transition in inflamed lung endothelial cells *in vitro*

Upon exposure to LPS, lung endothelial cells exhibited increased expression levels of N-cadherin and Vimentin compared to their unstimulated counterparts (p<0.001). However, co-culturing LPS-stimulated lung endothelial cells with naive and primed EVs derived from cASCs resulted in diminished expression of N-cadherin and Vimentin (p<0.01). In addition, the E-cadherin mRNA expression levels significantly increased in LPS-stimulated lung endothelial cells cultured with primed cASC-derived EVs in contrast to those cultured with naive cASC-derived EVs (p<0.001). This observation implied that primed cASC-derived EVs may impede the endothelial-to-mesenchymal transition during lung inflammation (Figure 6).

4 Discussion

In this study, we identified therapeutic efficacy factors of inflammatory cytokine-primed stem cell-derived EVs using RNAseq. In addition, the mechanism of lung recovery was confirmed by

¹ https://www.mirbase.org/



culturing primed EVs with lung endothelial cells with LPS-induced inflammation and analyzing EMT markers and inflammatory cytokines in the endothelial cells.

The pulmonary endothelium forms a continuous monolayer of squamous cells that line the internal surface of blood vessels (15). Together with the collagen-rich basement membrane, it serves to separate tissue microenvironments while also selectively connecting them to the bloodstream, thus contributing to tissue homeostasis (16). Previous studies have shown that acute or severe lung injury can lead to dense epithelial remodeling, resulting in hypoxic vasoconstriction and cytokine-induced inflammation in regions of severe damage. Additionally, it has been reported that recovery from lung endothelial cell injury is a key treatment goal for ALI (17). In our study, we confirmed the potential of primed EVs to promote lung repair using an *in vitro* model of LPS-induced inflamed lung endothelial

cells. As a result, we observed a decrease in the expression of pro-inflammatory cytokines and an increase in the expression of antiinflammatory cytokines, indicating the ability of primed EVs to alleviate inflammation and promote lung recovery.

TNF- α and IL-1 β are the most commonly studied cytokines in acute inflammation studies because of their proinflammatory effects, including leukocyte chemoattraction and phagocytosis stimulation (18). An imbalance between pro and anti-inflammatory cytokines is related to an increased mortality rate in patients with acute respiratory distress syndrome (19). TNF- α and IL-1 β have synergy during inflammation (20); hence, some studies have investigated the combined blockade of these cytokines simultaneously in imbalanced situations to control inflammation (18). Otherwise, IL-10 could suppress TNF- α production, inhibiting neutrophil activity and hence decreasing lung tissue damage (21). We found that both



FIGURE 2

Quantitative real-time polymerase chain reaction validated the increase of miR-16 and miR-502 in extracellular vesicles derived from naïve (n = 3) and tumor necrosis factor (TNF)- α and interferon (IFN)- γ -primed canine stem cells (n = 3). Among miRNAs in which significant changes were confirmed, significant elevations were confirmed for miR-16 and miR-502.



proinflammatory cytokines were expressed at lower levels in a lung inflammation co-cultured with EVs. In addition, IL-10 expression significantly increased in inflammatory lung cells co-cultured with primed cASCs. Previous studies have found that stem cells can produce immunomodulatory cytokines such as IL-10 to inhibit proinflammatory cytokine secretions such as TNF- α and IL-1 β , thereby alleviating pulmonary inflammation (22, 23). The ability of EVs demonstrated similar results, and our study further suggests a treatment strategy targeting cytokine balance in canine pulmonary injuries.

TGF- β 1 is correlated to macrophage and fibroblast recruitment (24), apoptosis in alveolar cells after damage (25), reactive oxygen species production (26) and EMT type II initiation (27). Ideally, the TGF- β 1 activation leads to tissue repair and adequate regeneration.



and ****p < 0.0001; ns. not significant.



However, highly activated TGF-\beta1 can harmfully affect tissues and cause fibrosis and scarring after healing. Therefore, targeting TGF-B1 after lung injury could result in successful treatment with minimal side effects. In this study, we found that primed EVs were more effective than naive EVs in reducing TGF-B1 levels. Therefore, this is a significant finding that may assist in further studies on potential therapies.

We demonstrated that primed EVs derived from cASCs were more effective than naive EVs in inhibiting EMT in vitro. Both primed EVs could more effectively control EMT progression than naive EVs, which is considered to occur after inflammatory stimuli are identified by the increased E-cadherin expression. E-cadherin is an epithelial protein that is downregulated during disassembly of epithelial cell junctions (28, 29). In addition, regardless of priming, EVs reduced the expression of N-cadherin and Vimentin, which are mesenchymal markers found in EMT progression (27). EMT is a key factor in lung fibrosis and tissue remodeling that results from chronic respiratory disease; inhibition of EMT has been proved to attenuate fibrosis (30-32). Although further research is required prior to its application in vivo, this finding is useful in developing treatments for chronic respiratory diseases.

EVs obtained from primed MSC have been reported to have higher immunoregulatory functions than EVs obtained from naïve MSC (33, 34). Similarly, mesenchymal stem cells primed with inflammatory cytokines are known to exhibit enhanced immuneregulating effects (35). As indicated by our results, EVs primed with inflammatory cytokines exhibit superior immunoregulatory results. The miRNA profile analysis of naive and primed cASC-derived EVs exhibited distinct expression in ALI cells, of which two miRNAs, miR-16 and miR-502, were upregulated in primed EVs compared to naive EVs. In previous studies, miR-16 has been proven to promote alveolar fluid clearance and decrease the expression of TGF- β , IL-1 β , and TNF- α , which all play a crucial role in lung injury (35-37). Our study further demonstrates the therapeutic importance of miR-16 in pulmonary disease, and suggests that it could be used as a prognostic biomarker for lung injury. The role of miR-502 in immune modulation remains uncertain; and to the best of our knowledge, no studies have investigated the role of miR-502 in lung diseases. However, several studies have identified miR-502 as an important tumor suppressor (38). Therefore, this miRNA may also have positive effects for respiratory disease treatment; however, further studies are required to verify these effects.

This study had some limitations. This study was conducted in vitro. According to previous studies, it has been reported that acute lung injury involves not only endothelial cells but also various immune cells, including neutrophils, lymphocytes, and macrophages, and studies on the therapeutic efficacy and complex mechanisms of primed EV through an in vivo ALI model is needed. Moreover, it is crucial to assess the potential side effects of primed EVs in an in vivo model. Pretreatment of stem cells with IFN-y upregulates MHC class II expression, leading to antigen



presentation to CD4⁺ T cells and immune activation (39, 40). Further research is necessary to ascertain whether the expression of MHC class II by stem cells affects EVs and whether immune activation occurs in animals injected with these EVs. The method used to identify EMT involved detecting markers that represented specific EMT stages. Therefore, no real-time method was used in this study, which is less sensitive for checking dynamic changes, such as EMT. Furthermore, in this study, ALI was induced by endotoxins. As many other causes of pulmonary diseases exist, the extrapolation of the results to other respiratory disease types is uncertain. Further studies are needed to determine the effect of the nine downregulated miRNAs, miR-184, miR-132, miR-130, miR-107, miR-1, let-7f, let-7g, let-7c, and miR-143, in lung inflammation. Although we found that primed EVs promoted lung endothelial cell proliferation, the specific mechanism underlying this phenomenon requires further study. Lastly, experiments were performed using a single dose of EV. Therefore, its capacity to repair lung damage in a dose-dependent manner is unknown. Additional research is needed on this as well.

Overall, we found that primed EVs had a better therapeutic effect in ALI *in vitro* model via suppressing TNF- α and IL-1 β expression, while elevating IL-10 expression. Additionally, primed EVs decreased the level of TGF- β 1 that induced EMT. This study suggests the potential of TNF- α and IFN- γ priming EVs from canine mesenchymal stem cells as a treatment for lung injury.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

Ethics statement

The animal studies were approved by the Institutional Animal Care and Use Committee of Kangwon National University (KNU), Republic of Korea, and in compliance with the authorized guidelines (KNU, Protocol No. KW-230912-3). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study.

Author contributions

J-SL: Writing – original draft, Investigation, Data curation, Conceptualization. Y-HJ: Writing – review & editing, Methodology. Y-HK: Writing – review & editing, Resources. J-HY: Writing – review & editing, Resources. J-OA: Writing – review & editing, Resources, Methodology. J-YC: Writing – review & editing, Resources, Methodology. J-HA: Writing – review & editing, Writing – original draft, Supervision, Resources, Methodology, Investigation, Funding acquisition, Conceptualization.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by "Regional Innovation Strategy (RIS)" through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) (2022RIS-005) and the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (RS-2023-00240708).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10.3389/fvets.2024.1411886

References

1. Herrero R, Sanchez G, Lorente JA. New insights into the mechanisms of pulmonary edema in acute lung injury. *Ann Transl Med.* (2018) 6:32. doi: 10.21037/atm.2017.12.18

2. Boiron L, Hopper K, Borchers A. Risk factors, characteristics, and outcomes of acute respiratory distress syndrome in dogs and cats: 54 cases. J Vet Emerg Crit Care. (2019) 29:173–9. doi: 10.1111/vec.12819

3. Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to translation. *J Immunol*. (2015) 194:855–60. doi: 10.4049/jimmunol.1402513

4. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. (2010) 23:243–52. doi: 10.1089/jamp.2009.0775

5. Lee JH, Park J, Lee JW. Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury. *Transfusion*. (2019) 59:876–83. doi: 10.1111/trf.14838

6. Zhang X, Cheng Z, Zeng M, He Z. The efficacy of extracellular vesicles for acute lung injury in preclinical animal models: a meta-analysis. *BMC Pulm Med.* (2024) 24:128. doi: 10.1186/s12890-024-02910-4

7. Gonzalez H, Mccarthy S, Masterson C, Byrnes D, Sallent I, Horan E, et al. Nebulised mesenchymal stem cell derived extracellular vesicles ameliorate *E. coli* induced pneumonia in a rodent model. *Stem Cell Res Ther.* (2023) 14:151. doi: 10.1186/s13287-023-03385-6

8. Monsel A, Zhu Y-G, Gennai S, Hao Q, Hu S, Rouby J-J, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. *Am J Respir Crit Care Med.* (2015) 192:324–36. doi: 10.1164/rccm.201410-1765OC

 An J-H, Li Q, Bhang D-H, Song W-J, Youn H-Y. TNF-α and INF-γ primed canine stem cell-derived extracellular vesicles alleviate experimental murine colitis. *Sci Rep.* (2020) 10:2115. doi: 10.1038/s41598-020-58909-4

10. Park S-M, An J-H, Lee J-H, Kim K-B, Chae H-K, Oh Y-I, et al. Extracellular vesicles derived from DFO-preconditioned canine AT-MSCs reprogram macrophages into M2 phase. *PLoS One*. (2021) 16:e0254657. doi: 10.1371/journal.pone.0254657

11. An J-H, Li Q, Ryu M-O, Nam A-R, Bhang D-H, Jung Y-C, et al. TSG-6 in extracellular vesicles from canine mesenchymal stem/stromal is a major factor in relieving DSS-induced colitis. *PLoS One.* (2020) 15:e0220756. doi: 10.1371/journal. pone.0220756

12. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol.* (2004) 5:R80–16. doi: 10.1186/gb-2004-5-10-r80

13. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing (2016) Available at: http://www.r-project.org/.

14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods*. (2001) 25:402–8. doi: 10.1006/meth.2001.1262

15. Niethamer TK, Stabler CT, Leach JP, Zepp JA, Morley MP, Babu A, et al. Defining the role of pulmonary endothelial cell heterogeneity in the response to acute lung injury. *eLife*. (2020) 9:e53072. doi: 10.7554/eLife.53072

16. Maniatis NA, Kotanidou A, Catravas JD, Orfanos SE. Endothelial pathomechanisms in acute lung injury. *Vasc Pharmacol.* (2008) 49:119–33. doi: 10.1016/j.vph.2008.06.009

17. Zhao Y, Ridge K, Zhao J. Acute lung injury, repair, and remodeling: Pulmonary endothelial and epithelial biology. *Mediators Inflamm.* (2017) 2017:9081521. doi: 10.1155/2017/9081521

18. Krishnadasan B, Naidu BV, Byrne K, Fraga C, Verrier ED, Mulligan MS. The role of proinflammatory cytokines in lung ischemia-reperfusion injury. *J Thorac Cardiovasc Surg.* (2003) 125:261–72. doi: 10.1067/mtc.2003.16

19. Donnelly SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Armstrong I, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. *Ann Intern Med.* (1996) 125:191–6. doi: 10.7326/0003-4819-125-3-199608010-00005

20. Dinarello CA. Proinflammatory cytokines. Chest. (2000) 118:503-8. doi: 10.1378/ chest.118.2.503

21. Inoue G. Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury. J Infect Chemother. (2000) 6:51–60. doi: 10.1007/s101560050050

22. Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. *Stem Cell Rev Rep.* (2015) 11:280–7. doi: 10.1007/s12015-014-9583-3

23. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci USA*. (2007) 104:11002–7. doi: 10.1073/pnas.0704421104

24. Fernandez IE, Eickelberg O. The impact of TGF- β on lung fibrosis: from targeting to biomarkers. *Proc Am Thorac Soc.* (2012) 9:111–6. doi: 10.1513/pats.201203-023AW

25. Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. *Nat Rev Cancer.* (2003) 3:807–20. doi: 10.1038/nrc1208

26. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. *Am J Respir Crit Care Med.* (2005) 172:417–22. doi: 10.1164/rccm.200501-017PP

27. Strutz F, Zeisberg M, Ziyadeh FN, Yang C-Q, Kalluri R, Müller GA, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. *Kidney Int.* (2002) 61:1714–28. doi: 10.1046/j.1523-1755.2002.00333.x

28. Boyer B, Vallés AM, Edme N. Induction and regulation of epithelialmesenchymal transitions. *Biochem Pharmacol.* (2000) 60:1091-9. doi: 10.1016/ S0006-2952(00)00427-5

29. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. *Am J Pathol.* (2009) 174:1588–93. doi: 10.2353/ ajpath.2009.080545

30. Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. *Annu Rev Physiol.* (2011) 73:413–35. doi: 10.1146/annurev-physiol-012110-142225

31. López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. *EMBO Mol Med.* (2009) 1:303–14. doi: 10.1002/emmm.200900043

32. O'Connor JW, Gomez EW. Biomechanics of TGFβ-induced epithelialmesenchymal transition: implications for fibrosis and cancer. *Clin Transl Med.* (2014) 3:1–13. doi: 10.1186/2001-1326-3-23

33. Di Trapani M, Bassi G, Midolo M, Gatti A, Takam Kamga P, Cassaro A, et al. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. *Sci Rep.* (2016) 6:24120. doi: 10.1038/srep24120

34. Domenis R, Cifù A, Quaglia S, Pistis C, Moretti M, Vicario A, et al. Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. *Sci Rep.* (2018) 8:13325. doi: 10.1038/ s41598-018-31707-9

35. Noronha NDC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. *Stem Cell Res Ther.* (2019) 10:1–21. doi: 10.1186/s13287-019-1259-0

36. Cai Z-G, Zhang S-M, Zhang Y, Zhou Y-Y, Wu H-B, Xu X-P. MicroRNAs are dynamically regulated and play an important role in LPS-induced lung injury. *Can J Physiol Pharmacol.* (2012) 90:37–43. doi: 10.1139/y11-095

37. Yang Y, Yang F, Yu X, Wang B, Yang Y, Zhou X, et al. miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury. *Biomed Pharmacother*. (2019) 112:108664. doi: 10.1016/j.biopha.2019.108664

38. Zhai H, Song B, Xu X, Zhu W, Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. *Oncogene*. (2013) 32:1570–9. doi: 10.1038/onc. 2012.167

39. Romieu-Mourez R, FrançOis MR, Boivin M-N, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN- γ , TGF- β , and cell density. *J Immunol.* (2007) 179:1549–58. doi: 10.4049/jimmunol.179.3.1549

40. Wijdeven RH, van Luijn MM, Wierenga-Wolf AF, Akkermans JJ, van den Elsen PJ, Hintzen RQ, et al. Chemical and genetic control of IFN γ -induced MHCII expression. *EMBO Rep.* (2018) 19:e45553. doi: 10.15252/embr.201745553